Moderna Stock Surges Over 550% Amid Cancer Vaccine Hype; Is It Too Late to Buy?
Moderna's stock has surged over 550% this year, driven by positive phase three trial results for its experimental cancer vaccine intismeran in combination with Merck’s Keytruda. The treatment showed statistically significant improvements in recurrence-free survival and distant metastasis-free survival among high-risk melanoma patients who had their tumors surgically removed. Despite the promising data, analysts remain cautious about Moderna's current valuation of nearly $200 per share, as its consensus price target is around just $77. While approval for intismeran could generate billions in revenue and mark a significant milestone for mRNA-based cancer treatments, it may not be enough to justify such high stock prices or restore profitability. The market has priced in substantial optimism about Moderna's future growth potential, but many experts believe the current valuation reflects too much speculation. Investors are advised to wait before buying into what could still be a risky biotech play.
Topics: biotech cancer vaccine Keytruda Moderna phase three trials